Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

PFIZER INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer Inc. : Pfizer Will Remove Claims on Breast and Colon Health From Centrum Label -Reuters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/05/2012 | 11:26pm CEST

Pfizer Inc. (>> Pfizer Inc.) said it will remove claims that its Centrum multivitamin supplements promote breast and colon health from labels over the next six months, following a complaint by a watchdog group, Reuters reported Thursday.

The company will also revise websites and advertising for Centrum, the report said.

The report said the Center for Science in the Public Interest sent a letter to Pfizer Chief Executive Ian Read in April outlining its complaints and threatening a lawsuit if the claims weren't removed.

In a statement, Pfizer said it "disagrees with CSPI's concerns, but has agreed to make these changes in order to fully resolve the issues raised by the organization," Reuters reported.

Full story at http://www.reuters.com/article/2012/07/05/pfizer-centrum-idUSL2E8I5BR820120705

Write to [email protected]

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
05/19PFIZER : Sen. Durbin Calls for Transparency From Pharmaceutical Companies in Adv..
AQ
05/19PFIZER : to present clinical advances from its growing portfolio & research pipe..
AQ
05/19PFIZER : Pfizers Lyrica meets primary endpoint in phase 3 pediatric epilepsy tri..
AQ
05/18PFIZER : LYRICA (pregabalin) Oral Solution CV Phase 3 Trial in Pediatric Epileps..
AQ
05/18AstraZeneca insists future is bright after big Crestor sales hit
RE
05/18PFIZER : FDA approves Pfizers Retacrit biosimilar to treat anaemia
AQ
05/18PFIZER : EpiPens remain available locally but are in short supply
AQ
05/18PFIZER : Around the World, People Living with Ulcerative Colitis Share Common Pe..
PU
05/18PFIZER : Looking for an EpiPen?
AQ
05/17PFIZER : Enforce anti-counterfeit, illicit drug use laws
AQ
More news
News from SeekingAlpha
2015Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update 
2015Antibiotics Stocks To Benefit From 21st Century Cures Act 
2015ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case 
2015DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb 
2015Pfizer's GL-2045 an Orphan Drug for CIDP 
Financials ($)
Sales 2018 54 391 M
EBIT 2018 20 753 M
Net income 2018 12 828 M
Debt 2018 21 840 M
Yield 2018 3,84%
P/E ratio 2018 15,87
P/E ratio 2019 15,11
EV / Sales 2018 4,31x
EV / Sales 2019 4,12x
Capitalization 212 B
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 39,6 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC212 424
JOHNSON & JOHNSON-11.36%332 184
PFIZER-1.41%212 424
NOVARTIS-6.55%202 969
ROCHE HOLDING LTD.-8.90%193 622
MERCK AND COMPANY5.10%158 916